Negative pressure wound therapy versus usual care for surgical wounds healing by secondary intention (SWHSI-2 trial): study protocol for a pragmatic, multicentre, cross surgical specialty, randomised controlled trial.
Negative pressure wound therapy
Randomised controlled trial
Secondary intention
Surgical wounds
Wound healing
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
18
05
2021
accepted:
27
09
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
28
10
2021
Statut:
epublish
Résumé
The majority of surgical wounds are closed (for example with sutures or staples) and so heal by primary intention. Where closure is not possible, or the wound subsequently breaks down, wounds may be left to heal from the bottom up (healing by secondary intention). Surgical wound healing by secondary intention (SWHSI) frequently presents a significant management challenge. Additional treatments are often required during the course of healing, and thus a significant financial burden is associated with treating these wounds. Increasingly, negative pressure wound therapy (NPWT) is used in the management of SWHSI. This wound dressing system provides a negative pressure (vacuum) to the wound, removing fluid into a canister, which is believed to be conducive to wound healing. Despite the increasing use of NPWT, there is limited robust evidence for the effectiveness of this device. A well-designed and conducted randomised controlled trial is now required to ascertain if NPWT is a clinically and cost-effective treatment for SWHSI. SWHSI-2 is a pragmatic, multi-centre, cross surgical specialty, two arm, parallel group, randomised controlled superiority trial. Adult patients with a SWHSI will be randomised to receive either NPWT or usual care (no NPWT) and will be followed up for 12 months. The primary outcome will be time to healing (defined as full epithelial cover in absence of a scab) in number of days since randomisation. Secondary outcomes will include key clinical events (hospital admission or discharge, treatment status, reoperation, amputation, antibiotic use and death), wound infection, wound pain, health-related quality of life, health utility and resource use. Given the increasing use of NPWT, despite limited high-quality supporting evidence, the SWHSI-2 Trial will provide robust evidence on the clinical and cost-effectiveness of NPWT in the management of SWHSI. The SWHSI-2 Trial opened to recruitment in May 2019 and is currently recruiting across 20 participating centres. ISRCTN 26277546 . Prospectively registered on 25 March 2019.
Sections du résumé
BACKGROUND
BACKGROUND
The majority of surgical wounds are closed (for example with sutures or staples) and so heal by primary intention. Where closure is not possible, or the wound subsequently breaks down, wounds may be left to heal from the bottom up (healing by secondary intention). Surgical wound healing by secondary intention (SWHSI) frequently presents a significant management challenge. Additional treatments are often required during the course of healing, and thus a significant financial burden is associated with treating these wounds. Increasingly, negative pressure wound therapy (NPWT) is used in the management of SWHSI. This wound dressing system provides a negative pressure (vacuum) to the wound, removing fluid into a canister, which is believed to be conducive to wound healing. Despite the increasing use of NPWT, there is limited robust evidence for the effectiveness of this device. A well-designed and conducted randomised controlled trial is now required to ascertain if NPWT is a clinically and cost-effective treatment for SWHSI.
METHODS
METHODS
SWHSI-2 is a pragmatic, multi-centre, cross surgical specialty, two arm, parallel group, randomised controlled superiority trial. Adult patients with a SWHSI will be randomised to receive either NPWT or usual care (no NPWT) and will be followed up for 12 months. The primary outcome will be time to healing (defined as full epithelial cover in absence of a scab) in number of days since randomisation. Secondary outcomes will include key clinical events (hospital admission or discharge, treatment status, reoperation, amputation, antibiotic use and death), wound infection, wound pain, health-related quality of life, health utility and resource use.
DISCUSSION
CONCLUSIONS
Given the increasing use of NPWT, despite limited high-quality supporting evidence, the SWHSI-2 Trial will provide robust evidence on the clinical and cost-effectiveness of NPWT in the management of SWHSI. The SWHSI-2 Trial opened to recruitment in May 2019 and is currently recruiting across 20 participating centres.
TRIAL REGISTRATION
BACKGROUND
ISRCTN 26277546 . Prospectively registered on 25 March 2019.
Identifiants
pubmed: 34696784
doi: 10.1186/s13063-021-05662-2
pii: 10.1186/s13063-021-05662-2
pmc: PMC8543414
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
739Subventions
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 17/42/94
Informations de copyright
© 2021. The Author(s).
Références
Int Wound J. 2015 Jun;12(3):265-75
pubmed: 23692188
J Tissue Viability. 2017 May;26(2):103-107
pubmed: 28049612
Ostomy Wound Manage. 2017 Mar;63(3):47-53
pubmed: 28355137
Diabetes Care. 2008 Apr;31(4):631-6
pubmed: 18162494
J Clin Epidemiol. 2018 May;97:86-94
pubmed: 29269021
Lancet. 2005 Nov 12;366(9498):1704-10
pubmed: 16291063
Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78; quiz 279-80
pubmed: 10219875
J Am Med Inform Assoc. 2016 Nov;23(6):1136-1142
pubmed: 27234601
Cogent Med. 2018 Jun 1;5(1):1483591
pubmed: 29938211
BJS Open. 2018 Apr 23;2(3):99-111
pubmed: 29951633
Br J Surg. 2005 Jun;92(6):665-72
pubmed: 15912490
BMJ. 2006 Apr 22;332(7547):969-71
pubmed: 16627519
Cochrane Database Syst Rev. 2009 Jul 08;(3):MR000008
pubmed: 19588449
Cochrane Database Syst Rev. 2015 Jun 04;(6):CD011278
pubmed: 26042534
J Infect Prev. 2017 Jul;18(4):170-179
pubmed: 28989524
Br J Surg. 2019 Feb;106(3):226-235
pubmed: 30556594
Langenbecks Arch Surg. 2012 Dec;397(8):1359-66
pubmed: 22875224
Int J Nurs Stud. 2018 Jan;77:29-38
pubmed: 29031127
Int J Nurs Stud. 2019 Jan;89:62-71
pubmed: 30343210
J Vasc Surg. 2014 Jan;59(1):145-51
pubmed: 24055512
Cochrane Database Syst Rev. 2018 Oct 17;10:CD010318
pubmed: 30328611
Dis Colon Rectum. 2014 Dec;57(12):1406-11
pubmed: 25380007
Cochrane Database Syst Rev. 2018 Feb 22;2:MR000013
pubmed: 29468635